| Abstract | MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is reported to selectively degenerate dopaminergic cells of the zona compacta of the substantia nigra and produce Parkinson's-like symptoms in man and animals. Although the exact mechanism of its neurotoxicity is not well defined, a major metabolite MPP+ may be responsible for the ultimate neuron toxicity. Several classes of drugs useful in Parkinson's disease are effective in reversing MPTP-induced neurotoxicity. Future pharmacological studies on the compound may unlock some of the mysteries of the age old disease, parkinsonism. |
| Authors | S K Kulkarni, A K Mehta, K O Aley, V K Shukla |
| Journal | Methods and findings in experimental and clinical pharmacology
(Methods Find Exp Clin Pharmacol)
Vol. 8
Issue 8
Pg. 485-9
(Aug 1986)
ISSN: 0379-0355 SPAIN |
| PMID | 3489146
(Publication Type: Journal Article)
|
| Chemical References |
- Monoamine Oxidase Inhibitors
- Pyridines
- Receptors, Dopamine
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
|
| Topics |
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- Animals
- Humans
- Monoamine Oxidase Inhibitors
(pharmacology)
- Parkinson Disease, Secondary
(chemically induced)
- Pyridines
(metabolism, pharmacology)
- Receptors, Dopamine
(drug effects)
|
